Advertisement
Screener

RELMADA THERAPEUTICS, INC. (RLMD) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

RELMADA THERAPEUTICS, INC. Operating Cash Flow

RELMADA THERAPEUTICS, INC. (RLMD) reported Operating Cash Flow of -$24.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.61M.
  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$15.07M.
  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$14.60M.
  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.72M.
  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$45.79M.
  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$51.76M.
  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$51.66M.
  • RELMADA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$103.80M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 21 monthNet Cash Provided by (Used in) Operating Activities 24 monthNet Cash Provided by (Used in) Operating Activities 27 monthNet Cash Provided by (Used in) Operating Activities 30 monthNet Cash Provided by (Used in) Operating Activities 33 monthNet Cash Provided by (Used in) Operating Activities 115 monthNet Cash Provided by (Used in) Operating Activities 118 month
2026-06-30-$9.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$24.67M
10-Q · filed 2026-08-06
-$39.27M
derived: sum of 3 quarters · filed 2026-08-06
-$45.99M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$15.07M
10-Q · filed 2026-05-12
-$29.66M
derived: sum of 2 quarters · filed 2026-05-12
-$36.39M
derived: sum of 3 quarters · filed 2026-05-12
-$42.79M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$14.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$21.32M
derived: sum of 2 quarters · filed 2026-03-19
-$27.72M
derived: sum of 3 quarters · filed 2026-08-06
-$45.79M
10-K · filed 2026-03-19
2025-09-30-$6.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$13.12M
derived: sum of 2 quarters · filed 2026-08-06
-$31.19M
10-Q · filed 2025-11-13
-$39.99M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$6.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$24.47M
10-Q · filed 2026-08-06
-$33.27M
derived: sum of 3 quarters · filed 2026-08-06
-$49.92M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$18.07M
10-Q · filed 2026-05-12
-$26.87M
derived: sum of 2 quarters · filed 2026-05-12
-$43.52M
derived: sum of 3 quarters · filed 2026-05-12
-$56.79M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$8.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$25.46M
derived: sum of 2 quarters · filed 2026-03-19
-$38.72M
derived: sum of 3 quarters · filed 2026-03-19
-$51.76M
10-K · filed 2026-03-19
2024-09-30-$16.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$29.92M
derived: sum of 2 quarters · filed 2025-11-13
-$42.96M
10-Q · filed 2025-11-13
-$53.21M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$13.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$26.30M
10-Q · filed 2025-08-07
-$36.55M
derived: sum of 3 quarters · filed 2025-08-07
-$48.18M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$13.04M
10-Q · filed 2025-05-12
-$23.29M
derived: sum of 2 quarters · filed 2025-05-12
-$34.92M
derived: sum of 3 quarters · filed 2025-05-12
-$48.19M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31-$10.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
-$21.88M
derived: sum of 2 quarters · filed 2025-03-27
-$35.15M
derived: sum of 3 quarters · filed 2025-03-27
-$51.66M
10-K · filed 2025-03-27
2023-09-30-$11.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$24.90M
derived: sum of 2 quarters · filed 2024-11-07
-$41.41M
10-Q · filed 2024-11-07
-$77.29M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$13.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
-$29.78M
10-Q · filed 2024-08-07
-$65.66M
derived: sum of 3 quarters · filed 2024-08-07
-$92.52M
derived: sum of 4 quarters · filed 2024-08-07
2023-03-31-$16.51M
10-Q · filed 2024-05-08
-$52.39M
derived: sum of 2 quarters · filed 2024-05-08
-$79.25M
derived: sum of 3 quarters · filed 2024-05-08
-$100.88M
derived: sum of 4 quarters · filed 2024-05-08
2022-12-31-$35.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
-$62.75M
derived: sum of 2 quarters · filed 2024-03-19
-$84.37M
derived: sum of 3 quarters · filed 2024-03-19
-$103.80M
10-K · filed 2024-03-19
2022-09-30-$26.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$48.49M
derived: sum of 2 quarters · filed 2023-11-08
-$67.92M
10-Q · filed 2023-11-08
-$105.58M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30-$21.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
-$41.06M
10-Q · filed 2023-08-08
-$78.72M
derived: sum of 3 quarters · filed 2023-08-08
-$99.63M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31-$19.43M
10-Q · filed 2023-05-11
-$57.09M
derived: sum of 2 quarters · filed 2023-05-11
-$78.01M
derived: sum of 3 quarters · filed 2023-05-11
-$95.22M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$37.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
-$58.58M
derived: sum of 2 quarters · filed 2023-03-23
-$75.79M
derived: sum of 3 quarters · filed 2023-03-23
-$91.87M
10-K · filed 2023-03-23
2021-09-30-$20.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$38.13M
derived: sum of 2 quarters · filed 2022-11-10
-$54.21M
10-Q · filed 2022-11-10
-$61.14M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$17.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$33.30M
10-Q · filed 2022-08-11
-$40.23M
derived: sum of 3 quarters · filed 2022-08-11
-$52.73M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$16.09M
10-Q · filed 2022-05-05
-$23.01M
derived: sum of 2 quarters · filed 2022-05-05
-$35.52M
derived: sum of 3 quarters · filed 2022-05-05
-$40.47M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31-$6.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25
-$19.43M
derived: sum of 2 quarters · filed 2022-03-25
-$24.38M
derived: sum of 3 quarters · filed 2022-03-25
-$27.81M
10-K · filed 2022-03-25
2020-09-30-$12.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$17.46M
derived: sum of 2 quarters · filed 2021-11-12
-$20.88M
10-Q · filed 2021-11-12
-$24.76M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$4.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
-$8.38M
10-Q · filed 2021-08-10
-$12.26M
derived: sum of 3 quarters · filed 2021-08-10
-$14.79M
derived: sum of 4 quarters · filed 2021-08-10
2020-03-31-$3.42M
10-Q · filed 2021-05-12
-$7.30M
derived: sum of 2 quarters · filed 2021-05-12
-$9.84M
derived: sum of 3 quarters · filed 2021-05-12
-$13.51M
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31-$3.88M
derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-24
-$6.41M
10-K · filed 2021-03-24
-$10.08M
derived: sum of 3 quarters · filed 2021-03-24
-$12.09M
10-K · filed 2021-03-24
2019-09-30-$2.53M
10-Q · filed 2019-11-13
-$6.20M
derived: sum of 2 quarters · filed 2020-08-12
-$8.21M
10-Q · filed 2020-11-12
-$11.36M
derived: sum of 4 quarters · filed 2020-08-12
2019-06-30-$3.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
-$5.68M
10-Q · filed 2020-08-12
-$8.83M
derived: sum of 3 quarters · filed 2020-08-12
-$10.50M
10-K · filed 2021-03-24
2019-03-31-$2.01M
10-Q · filed 2020-05-15
-$5.16M
derived: sum of 2 quarters · filed 2020-05-15
-$6.83M
10-Q · filed 2019-05-15
-$9.10M
derived: sum of 4 quarters · filed 2020-05-15
2018-12-31-$3.15M
derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26
-$4.82M
10-KT · filed 2020-03-26
-$7.09M
derived: sum of 3 quarters · filed 2020-03-26
-$8.71M
derived: sum of 4 quarters · filed 2020-03-26
2018-09-30-$1.67M
10-Q · filed 2019-11-13
-$3.94M
derived: sum of 2 quarters · filed 2020-03-26
-$5.56M
derived: sum of 3 quarters · filed 2020-03-26
-$6.69M
derived: sum of 4 quarters · filed 2020-03-26
2018-06-30-$2.27M
derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26
-$3.89M
derived: sum of 2 quarters · filed 2020-03-26
-$5.02M
derived: sum of 3 quarters · filed 2020-03-26
-$6.00M
10-KT · filed 2020-03-26
2018-03-31-$1.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15
-$2.76M
derived: sum of 2 quarters · filed 2019-05-15
-$3.74M
10-Q · filed 2019-05-15
-$4.75M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$1.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13
-$2.11M
10-Q · filed 2019-02-13
-$3.13M
derived: sum of 3 quarters · filed 2019-02-13
-$4.98M
derived: sum of 4 quarters · filed 2019-02-13
2017-09-30-$979.05K
10-Q · filed 2018-11-13
-$2.00M
derived: sum of 2 quarters · filed 2018-11-13
-$3.85M
derived: sum of 3 quarters · filed 2018-11-13
-$5.30M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30-$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-28
-$2.87M
derived: sum of 2 quarters · filed 2018-09-28
-$4.32M
derived: sum of 3 quarters · filed 2018-09-28
-$6.47M
10-K · filed 2018-09-28
2017-03-31-$1.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14
-$3.31M
derived: sum of 2 quarters · filed 2018-05-14
-$5.45M
10-Q · filed 2018-05-14
-$8.28M
derived: sum of 4 quarters · filed 2018-05-14
2016-12-31-$1.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-12
-$3.60M
10-Q · filed 2018-02-12
-$6.42M
derived: sum of 3 quarters · filed 2018-02-12
-$10.05M
derived: sum of 4 quarters · filed 2018-02-12
2016-09-30-$2.14M
10-Q · filed 2016-11-10
-$4.97M
derived: sum of 2 quarters · filed 2017-09-28
-$8.60M
derived: sum of 3 quarters · filed 2017-09-28
-$12.07M
derived: sum of 4 quarters · filed 2017-09-28
2016-06-30-$2.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28
-$6.45M
derived: sum of 2 quarters · filed 2017-09-28
-$9.93M
derived: sum of 3 quarters · filed 2017-09-28
-$13.14M
10-K · filed 2017-09-28
2016-03-31-$3.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15
-$7.10M
derived: sum of 2 quarters · filed 2017-05-15
-$10.32M
10-Q · filed 2017-05-15
-$14.81M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31-$3.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-10
-$6.69M
10-Q · filed 2017-02-10
-$11.18M
derived: sum of 3 quarters · filed 2017-02-10
-$15.61M
derived: sum of 4 quarters · filed 2017-02-10
2015-09-30-$3.22M
10-Q · filed 2016-11-10
-$7.70M
derived: sum of 2 quarters · filed 2016-11-10
-$12.14M
derived: sum of 3 quarters · filed 2016-11-10
-$17.12M
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30-$4.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09
-$8.92M
derived: sum of 2 quarters · filed 2016-09-09
-$13.90M
derived: sum of 3 quarters · filed 2016-09-09
-$16.23M
10-K · filed 2016-09-09
2015-03-31-$4.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09
-$9.42M
derived: sum of 2 quarters · filed 2016-05-09
-$11.74M
10-Q · filed 2016-05-09
-$12.88M
derived: sum of 4 quarters · filed 2016-05-09
2014-12-31-$4.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05
-$7.31M
10-Q · filed 2016-02-05
-$8.45M
derived: sum of 3 quarters · filed 2016-02-05
-$9.47M
derived: sum of 4 quarters · filed 2016-02-05
2014-09-30-$2.32M
10-Q · filed 2015-11-06
-$3.47M
derived: sum of 2 quarters · filed 2015-11-06
-$4.49M
derived: sum of 3 quarters · filed 2015-11-06
2014-06-30-$1.15M
derived: 10-K 6 month − 8-K 3 month · filed 2015-09-11
-$2.16M
10-K · filed 2015-09-11
2014-03-31-$1.02M
8-K · filed 2014-05-27
-$1.85M
10-Q · filed 2015-05-15
-$10.82M
8-K · filed 2014-05-27
2014-02-28-$3.54K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-15
-$12.66K
10-Q · filed 2014-04-15
-$39.07K
10-Q · filed 2014-04-15
2013-12-31-$420.58K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13
-$829.28K
10-Q · filed 2015-02-13
-$2.24M
10-K · filed 2015-09-11
-$9.80M
8-K · filed 2014-05-27
2013-11-30-$9.12K
10-Q · filed 2014-01-13
-$35.53K
10-Q · filed 2014-01-13
2013-09-30-$408.70K
10-Q · filed 2014-11-07
2013-08-31-$5.37K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16
-$10.41K
derived: sum of 2 quarters · filed 2013-12-16
-$11.86K
10-K · filed 2013-12-16
-$26.41K
10-K · filed 2013-12-16
2013-05-31-$5.04K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-12
-$6.49K
10-Q · filed 2013-07-12
-$21.04K
10-Q · filed 2013-07-12
2013-03-31-$399.88K
8-K · filed 2014-05-27
2013-02-28-$2.94K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-15
-$1.45K
10-Q · filed 2014-04-15
-$4.79K
derived: sum of 3 quarters · filed 2014-04-15
-$6.78K
derived: sum of 4 quarters · filed 2014-04-15
-$16.00K
10-Q · filed 2013-05-03
2012-12-31-$1.58M
10-KT · filed 2014-09-09
2012-11-30$1.50K
10-Q · filed 2014-01-13
-$1.85K
derived: sum of 2 quarters · filed 2014-01-13
-$3.83K
derived: sum of 3 quarters · filed 2014-01-13
2012-08-31-$3.34K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16
-$5.33K
derived: sum of 2 quarters · filed 2013-12-16
-$7.57K
10-K · filed 2013-12-16
2012-05-31-$1.99K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-12
-$4.22K
10-Q · filed 2013-07-12
2012-02-29-$2.23K
10-Q · filed 2013-05-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63